Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)

NCT ID: NCT02667574

Last Updated: 2022-10-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 55 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-11-18
• Study Completion Date: 2020-07-15

Brief Summary

Open-label, non-comparative, multicenter, phase II study of Vismodegib in patients with locally advanced BCC.

Detailed Description

Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg (in accordance with the product SmPC) per administration. One cycle of therapy will be defined as 28 days of treatment. The treatment will be renewed once a month depending on the product tolerance.

The trial will consist of a Screening Period (Day -28 to -1), a Treatment Period (Day 1 to BOR), one End of Treatment Visit, one Surgery Visit and 8 Safety Follow-Up Visits after the last dose of Vismodegib (+/- 5 days). Day 1 of the study will be defined as the first day a patient receives Vismodegib.

Conditions

Basal Cell Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

open-label

Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg per administration (in accordance with the product SmPC). One cycle of therapy will be defined as 28 days of treatment. The treatment will be renewed once a month depending on the product tolerance

Group Type: OTHER

ERIVEDGE

Intervention Type: DRUG

Interventions

ERIVEDGE

Intervention Type: DRUG

Other Intervention Names

VISMODEGIB

Eligibility Criteria

Inclusion Criteria

1. Patients with BCC, which surgery stage is A, B or C (cf. Appendix 3: Definition of surgery stages), with a diameter ≥ 3cm in zones at intermediate risk of tumor recurrence and a BCC with a diameter of ≥ 2 cm in the zones at higher risk of tumor recurrence. According to the HAS recommendations, two zones are taken into consideration:

• Zones at intermediate risk of tumor recurrence: forehead, cheek, chin, neck and scalp
• Zones at higher risk of tumor recurrence: nose and periorificial sites of the cephalic extremity

2. The decision to include the patient in this study should be taken during the Pluridisciplinary Committee Meeting (RCP). During this RCP, the radiotherapy should be considered as an inadequate treatment. (If the radiotherapist is absent during the meeting, his opinion should be documented in the patient's medical record).

3. Written informed consent

4. Age ≥ 18 years old

5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0, 1, or 2

6. At least one histologically confirmed lesion...

8. Patients with measurable and/or non-measurable disease (as defined by RECIST, v1.1)

9. Adequate organ function, as evidenced by the following laboratory results:

• Hemoglobin > 8.5 g/dL
• Granulocyte count ≥ 1000/μL
• Platelet count ≥ 75,000/μL
• Aspartate transaminase (AST ) and alanine transaminase (ALT) ≤ 3 × upper limit of normal (ULN)
• Total bilirubin ≤ 1.5 × ULN or within 3 × ULN for patients with documented Gilbert syndrome

10. Negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥ 1 year.

11. Women of childbearing potential must use one highly-effective method of contraception and one barrier method of contraception during treatment and for 24 months after the final dose. Highly-effective methods of contraception are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (e.g., implants, injectables, or intra-uterine devices; refer to Appendix 8 for more details). At the discretion of the Investigator, acceptable methods of contraception may include total abstinence. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, and postovulation methods] and withdrawal are not acceptable methods of contraception.).

12. For male patients with female partners of childbearing potential, agreement top use a condom with spermicide, even after vasectomy, during sexual intercourse with partners while being treated with Vismodegib and for two months after completion of study treatment

13. For male patients, agreement not to donate semen during the study and for 24 months after discontinuation of Vismodegib

14. Agreement not to donate blood or blood products during the study and for at least 24 months after discontinuation of Vismodegib.

15. Life expectancy > 12 weeks

16. Patients covered by a Health Insurance System

Exclusion Criteria

1. Inability or unwillingness to swallow capsules

2. Patients with BCC situated out of the head or the neck area

3. Pregnancy or lactation

4. Concurrent non-protocol-specified anti-tumor therapy (e.g., chemotherapy, other targeted therapy or photodynamic therapy

5. Chemotherapy within 4 weeks prior to enrollment

6. Participation in another clinical trial within 4 weeks prior to enrollment

7. Radiotherapy within 6 months prior to enrolment

8. Metastatic BCC

9. Uncontrolled medical illnesses such as infection requiring treatment with intravenous antibiotics.

10. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or that renders the patient at high risk from treatment complications.

11. Patients with a rare hereditary problem of galactose intolerance, primary hypolactasia or glucose-galactose malabsorption (according to the product SmPC).

12. Patients unable or unwilling to comply with the protocol requirements

13. Patients in emergency situations

14. Patients kept in detention

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hoffmann-La Roche

INDUSTRY

Sponsor Role: collaborator

University Hospital, Lille

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Laurent MORTIER, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Lille

Locations

CHU de Besançon

Besançon, , France

Hôpital St André

Bordeaux, , France

CH de Boulogne sur mer

Boulogne-sur-Mer, , France

CHU - Hôpital d'Estaing

Clermont-Ferrand, , France

CHU Bocage

Dijon, , France

Clinique de Dermatologie

Lille, , France

Hôpital de la Timone

Marseille, , France

Hôpital Saint Eloi

Montpellier, , France

Hôpital Bichat

Paris, , France

Hôpital Saint-Louis

Paris, , France

CHU Ambroise Paré

Paris, , France

Hôpital Haut-Lévêque

Pessac, , France

Centre hospitalier Lyon Sud

Pierre-Bénite, , France

Hôpital Robert Debré

Reims, , France

Hôpital Pontchaillou

Rennes, , France

Hôpitaux de Brabois

Vandœuvre-lès-Nancy, , France

Institut Gustave Roussy

Villejuif, , France

Countries

France

Other Identifiers

2013-004338-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

2013_36

Identifier Type: -

Identifier Source: org_study_id